SERPINA1 and alpha 1-antitrypsin deficiency: A recently published pilot study [113] has reported that intravenous administration of AAT at the rate of 120 mg/kg/wk is even safe to use and effective compared to the current standard single dose (60 mg/kg/wk) treating AATD.